SCHEMBL10117140

SCHEMBL10117140

CCOC(=O)c1ccc(N2C(=O)C(=O)C(C(=O)c3ccc(Cl)cc3)C2c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 12/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 3/20 0.48
USP2 O75604 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TP53 P04637 2/20 0.48
GAA P10253 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47
HTT P42858 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
AGTR1 P30556 1/20 0.47
SIRT3 Q9NTG7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116797 0.97 P2RX3 (0.52) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL10116812 0.94 P2RX3 (0.58) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL15139582 0.92 P2RX3 (0.55) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL10116778 0.90 P2RX3 (0.55) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL10116756 0.89 P2RX3 (0.61) P2RX3MEN1KMT2AALDH1A1USP2
SCHEMBL10117117 0.89 P2RX3 (0.61) P2RX3MEN1KMT2AALDH1A1USP2
SCHEMBL10116698 0.89 P2RX3 (0.62) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL15139586 0.89 P2RX3 (0.54) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL10116758 0.88 P2RX3 (0.52) P2RX3MEN1KMT2ALMNAKDM4E
SCHEMBL13521325 0.88 P2RX3 (0.53) P2RX3MEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497263-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2013-07-30 US disclosed
US-8497263-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2013-07-30 US disclosed
US-8101644-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2012-01-24 US disclosed
US-8101644-B2 Pyrrolinone derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2012-01-24 US disclosed
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KAI HIROYUKI (JP) 2012-01-12 US disclosed
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KAI HIROYUKI (JP) 2012-01-12 US disclosed
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2010-08-19 US disclosed
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010199-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX2, P2RX1 P2RX3 1/4885MEN1 3731/4885KMT2A 3720/4885
US-20100210632-A1 NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME P2RX3, P2RX2, P2RX1 P2RX3 1/4885MEN1 3731/4885KMT2A 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.